JP4210190B2 - Stress relieving agent - Google Patents

Stress relieving agent Download PDF

Info

Publication number
JP4210190B2
JP4210190B2 JP2003338518A JP2003338518A JP4210190B2 JP 4210190 B2 JP4210190 B2 JP 4210190B2 JP 2003338518 A JP2003338518 A JP 2003338518A JP 2003338518 A JP2003338518 A JP 2003338518A JP 4210190 B2 JP4210190 B2 JP 4210190B2
Authority
JP
Japan
Prior art keywords
extract
stress
actin
stress relieving
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003338518A
Other languages
Japanese (ja)
Other versions
JP2005104877A (en
Inventor
勲 灘岡
豊 指田
祥浩 三巻
和樹 渡辺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Breweries Ltd
Original Assignee
Asahi Breweries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Breweries Ltd filed Critical Asahi Breweries Ltd
Priority to JP2003338518A priority Critical patent/JP4210190B2/en
Publication of JP2005104877A publication Critical patent/JP2005104877A/en
Application granted granted Critical
Publication of JP4210190B2 publication Critical patent/JP4210190B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

アクティンまたはそれを含有する植物抽出物を有効成分とするストレス緩和剤に関する。   The present invention relates to a stress relieving agent containing actin or a plant extract containing it as an active ingredient.

現代はストレス過負荷の時代であり、現代に暮らすものは多かれ少なかれ、負荷されたストレスの影響のもとに暮らしている。このようなストレスの人体に及ぼす影響は近年になって詳細に調査されるようになり、予想外に大きな影響を及ぼすことが明確になりつつある。近年社会的に衝撃を与えるような犯罪事件が多いのも、このようなストレスの影響によるものだといわれている。ストレスの原因を減らすことが根本的な解決手段であるが、それが困難なのが現状であり、ストレスの影響を緩和させるような食品素材が望まれている。   The present age is an era of stress overload, and what lives in the present age is more or less living under the influence of stress. The impact of such stress on the human body has recently been investigated in detail, and it is becoming clear that it has an unexpectedly large impact. In recent years, it is said that there are many criminal cases that have a social impact due to the effects of such stress. Reducing the cause of stress is a fundamental solution, but it is difficult to do so at present, and food materials that reduce the effects of stress are desired.

ストレスの影響からの回復やストレスによる鬱状態の改善が期待される植物抽出物、漢方生薬抽出物が知られている。たとえば、マメ科コンメイケットウ、カンラン科モツヤクジュ、ユリ科アロエ、オミナエシ科カンショウコウ、セリ科サンゴナ、ヤドリギ科ソウキセイ、マオウ科シナマオウ、ショウガ科ショウガ、マメ科クズ、キンポウゲ科オキナグサ、ミカン科ハクセン、セリ科キョウカツの漢方生薬の基源植物のエッセンスからなるストレスの悪影響からの回復促進剤(例えば、特許文献1参照)や、羅布麻抽出物を含有する抗鬱作用を有する食品、栄養補助食品、医薬品(例えば、特許文献2参照)がある。 Plant extracts and herbal medicine extracts that are expected to recover from the effects of stress and to improve depression due to stress are known. For example, leguminous confectionery, orchidaceae spruce, lilyaceae aloe vera, coriaceae coral coral, coriaceae coral, mistletoe coriander, cicada cinamao, ginger ginger, legume kudu, buttercup genus, citrus cactus, seri Foods that have an antidepressant effect, including an accelerator for recovery from adverse effects of stress (for example, see Patent Document 1) consisting of the essence of a herbal essence of Chinese herbal medicines, and a rafu extract (See, for example, Patent Document 2).

また、ブラックコホシュは、シミシフガ・ラセモサ(Cimicifuga racemosa)の学名で、キンポウゲ科に属する植物である。その主成分のシミシフギン(Cimicifugin)は急激なエストロゲンの減少を抑えて、更年期障害の症状を和らげることが知られている。ブラックコホシュ抽出物の使用については、心臓血管疾患、特にアテローム性動脈硬化症、骨粗鬆症及び更年期障害の治療及び/又は予防、例えば一過性熱感の予防又は軽減のためのエストロゲン型期間選択性薬剤として開示されている(特許文献3)。しかし、ストレス緩和作用は言及されていない。 Black cohosh is a plant belonging to the family Ranunculaceae under the scientific name of Cimicifuga racemosa. Its main component, Cimicifugin, is known to relieve symptoms of menopause by suppressing rapid estrogen loss. As for the use of black cohosh extract, as an estrogen-type period selective drug for the treatment and / or prevention of cardiovascular diseases, especially atherosclerosis, osteoporosis and menopause, for example prevention or alleviation of transient heat sensation (Patent Document 3). However, no stress mitigating action is mentioned.

特開2001−192338号公報JP 2001-192338 A 特開2002−201139号公報JP 2002-201139 A 特表2002−506827号公報Japanese translation of PCT publication No. 2002-506827

本発明の目的は、天然由来で、しかも長期服用しても安全なストレス緩和剤を提供することである。   An object of the present invention is to provide a stress relieving agent that is naturally derived and that is safe even after long-term use.

本発明者らは、ブラックコホシュにストレス緩和作用があることを見出した(特願2000−370604)。さらに鋭意検討した結果、ブラックコホシュ根中のアクティン(Actein)が特にストレス緩和作用を示すことを見出し、本発明を完成するに至った。   The present inventors have found that black cohosh has a stress relieving action (Japanese Patent Application No. 2000-370604). As a result of further intensive studies, it was found that Actein in black cohosh roots exhibits a particularly stress relieving action, and the present invention has been completed.

したがって、本発明はアクティンを有効成分とするストレス緩和剤を提供することである。さらに、上記ストレス緩和剤を含有する食品、機能性食品、飲料、医薬品を提供する。 Accordingly, the present invention is to provide a stress relaxation agent comprising as an active ingredient activate emissions. Furthermore, foods, functional foods, beverages and pharmaceuticals containing the stress relieving agent are provided.

本発明のアクティンはストレス緩和作用を示し、ストレス緩和剤の成分として有用である。また、アクティンはストレス緩和を目的とした食品、栄養補助食品、機能性食品、医薬品などの組成物に利用できる。 Akti down of present invention show stress relaxation effect and it is useful as a component of stress reliever. Further, Akti emissions are available food for the purpose of stress relaxation, dietary supplements, functional food, a composition such as a medicament.

本発明におけるストレス緩和剤にはアクティンを用いることができる。アクティンを含有する植物抽出物としてはブラックコホシュ抽出物があげられるが、これに限定されるものではない。ブラックコホシュ抽出物としては、ブラックコホシュを水あるいはエタノールまたは含水エタノールあるいは有機溶剤で抽出、濃縮して得られる抽出物、およびここで得られる抽出物を限外濾過膜を用いて精製して得られるものである。ブラックコホシュの葉、茎、花、根茎等を抽出に用いることができるが、根茎が好ましい。含水エタノールとしてはエタノール濃度10〜95%で、30〜70%が好ましく、さらに50%が好ましい。 The stress relaxation agent in the present invention may be used activate emissions. The plant extract containing actin includes, but is not limited to, black cohosh extract. The black cohosh extract is an extract obtained by extracting and concentrating black cohosh with water, ethanol, hydrous ethanol, or an organic solvent, and obtained by purifying the extract obtained here using an ultrafiltration membrane. is there. Black cohosh leaves, stems, flowers, rhizomes and the like can be used for extraction, but rhizomes are preferred. The hydrous ethanol has an ethanol concentration of 10 to 95%, preferably 30 to 70%, and more preferably 50%.

本発明はさらに、アクティンを含むストレス緩和作用を有する組成物を提供し、この組成物は好ましくは食品、栄養補助食品、機能性食品または医薬品の形態である。本発明の組成物が医薬用組成物であるときの投与方法は特に限定されるものではないが、経口投与可能な剤形が好ましい。本発明の医薬用組成物は種々の剤形とすることができる。例えば、経口投与のためには、錠剤、カプセル剤、散剤、顆粒剤、丸剤、液剤、乳剤、トローチ剤、懸濁剤、溶液剤、酒精剤、シロップ剤、抽出物剤、エリキシル剤とすることができるが、これらに限定されない。また、製剤には薬剤的に許容できる種々の担体を加えることができる。例えば、賦形剤、結合剤、崩壊剤、滑沢剤、着香剤、着色剤、甘味剤、矯味剤、溶解補助剤、懸濁化剤、乳化剤、コーティング剤、ビタミンC、抗酸化剤を含むことができるが、これらに限定されない。 The present invention further provides a composition having a stress relaxation effects including activate emissions, the composition is preferably food, dietary supplements, functional foods or pharmaceutical form. The administration method when the composition of the present invention is a pharmaceutical composition is not particularly limited, but an orally administrable dosage form is preferred. The pharmaceutical composition of the present invention can be in various dosage forms. For example, for oral administration, tablets, capsules, powders, granules, pills, solutions, emulsions, troches, suspensions, solutions, spirits, syrups, extracts, elixirs Can be, but is not limited to. In addition, various pharmaceutically acceptable carriers can be added to the preparation. For example, excipients, binders, disintegrants, lubricants, flavoring agents, coloring agents, sweeteners, flavoring agents, solubilizers, suspending agents, emulsifiers, coating agents, vitamin C, antioxidants It can include but is not limited to these.

本発明の医薬用組成物の投与量は、一般的には、アクティンを成人一日量として0.1mg〜200mg、好ましくは0.1mg〜100mg、ブラックコホシュ抽出物に換算して成人1日用量として1mg〜2000mg、好ましくは1mg〜1000mgを使用する。もちろん個別的に、投与されるヒトの年齢、体重、症状、投与経路、投与期間、治療経過等に応じて変化させることもできる。1日あたりの量を数回に分けて投与することもできる。また、他のストレス緩和剤や治療法と組み合わせて投与することもできる。   The dosage of the pharmaceutical composition of the present invention is generally 0.1 mg to 200 mg, preferably 0.1 mg to 100 mg as a daily dose of actin for adults, and the daily dose for adults in terms of black cohosh extract. 1 mg to 2000 mg, preferably 1 mg to 1000 mg is used. Of course, it can be changed individually according to the age, weight, symptoms, administration route, administration period, course of treatment, etc. of the administered human. The daily dose can be administered in several divided doses. It can also be administered in combination with other stress relieving agents and treatments.

本発明の組成物は、食品又は栄養補助食品の形態とすることもできる。例えば、アクティンを原材料に配合することにより、麺類、パン、キャンディー、ゼリー、クッキー、スープ、健康飲料の形態とすることができる。このような食品、栄養補助食品、機能性食品にはアクティンの他に、鉄、カルシウム等の無機成分、種々のビタミン類、オリゴ糖、キトサン等の食物繊維、大豆抽出物等のタンパク質、レシチンなどの脂質、ショ糖、乳糖等の糖類を加えることができる。 The composition of the present invention may be in the form of a food or a dietary supplement. For example, by incorporating activate on to the raw material, can be noodles, bread, candies, jellies, cookies, soups, and the form of a health drink. Such foods, dietary supplements, in addition to activate down in functional foods, iron, inorganic components such as calcium, various vitamins, oligosaccharides, dietary fibers such as chitosan, proteins, such as soybean extract, lecithin Sugars such as lipids, sucrose, and lactose can be added.

また、本発明のアクティンに羅布麻抽出物、高麗ニンジン抽出物、イチョウ葉抽出物、ツボクサ抽出物、エゾウコギ抽出物、オウギ抽出物、ガラナ抽出物、マカ抽出物、タンポポ抽出物、アーティチョーク抽出物、ゲンチアナ抽出物、シサンドラ抽出物、西洋カボチャ抽出物、大豆抽出物、甘草抽出物、当帰抽出物、西洋ニンジンボク抽出物、ザクロ抽出物、ヤムイモ抽出物、オオアワダチソウ抽出物、キダチアロエ抽出物、田七ニンジン抽出物、チャボトケイソウ抽出物、ヤドリギ抽出物などを組み合わせることにより、精神的ストレスから陥る症状の緩和効果を有する食品、栄養補助食品、機能性食品、医薬品などの組成物が得られる。
In addition, Luo cloth hemp extract to activate emission of the present invention, ginseng extract, ginkgo leaf extract, Centella asiatica extract, Siberian ginseng extract, Astragali extract, guarana extract, maca extract, dandelion extract, artichoke extract , Gentian extract, shisandra extract, western pumpkin extract, soy extract, licorice extract, toki extract, western carrot extract, pomegranate extract, yam extract, prickly pear extract, prickly aloe extract, rice field Compositions such as foods, dietary supplements, functional foods, pharmaceuticals and the like having an effect of alleviating symptoms caused by mental stress can be obtained by combining seven carrot extracts, chabotodia extract, mistletoe extract, and the like.

アクティン(Actein)抽出、精製、単離の検討
ブラックコホシュの根および根茎(5.2kg)を熱メタノールで抽出(3時間、2回)し、抽出液を減圧下濃縮した。濃縮エキス445gを30%メタノールにて懸濁させ、DiaionHP−20カラムクロマトグラフィーに付し、30%メタノール、50%メタノール、メタノール、エタノール、酢酸エチルで順次極性を下げながら溶出させ、5つの粗画分に分画した。得られたメタノール溶出画分181gをシリカゲルカラムクロマトグラフィー[クロロホルム−メタノール(19:1;9:1;4:1;2:1)→メタノール]により7つの画分(フラクションA〜G)に分画した。フラクションCをシリカゲルカラムクロマトグラフィー[クロロホルム−メタノール(19:1)]、オクタデシルシラン化(ODS)シリカゲルカラムクロマトグラフィー[アセトニトリル−水(1:1)]、Sephadex LH−20[メタノール]により、さらに5つ(フラクションC−1〜C−5)に分画した。フラクションC−3をメタノールに溶解し,室温で放置しておいたところ沈殿が生じた。沈殿物を濾取し、シリカゲルカラムクロマトグラフィー[クロロホルム−メタノール(30:1;19:1)]、ODS
シリカゲルカラムクロマトグラフィー[アセトニトリル−水(1:1)]、セミ分取ODS HPLC[アセトニトリル−メタノール−水(1:1:1)]を繰り返し行うことにより精製して、アクティン(3.2g)を単離した。
Study on Actein extraction, purification and isolation
Black cohosh roots and rhizomes (5.2 kg) were extracted with hot methanol (3 hours, twice), and the extract was concentrated under reduced pressure. Suspend 445 g of concentrated extract in 30% methanol, apply to DiaionHP-20 column chromatography, elute with 30% methanol, 50% methanol, methanol, ethanol, ethyl acetate in order of decreasing polarity. It was fractionated into minutes. 181 g of the obtained methanol-eluted fraction was separated into 7 fractions (fractions A to G) by silica gel column chromatography [chloroform-methanol (19: 1; 9: 1; 4: 1; 2: 1) → methanol]. I drew it. Fraction C was further separated by silica gel column chromatography [chloroform-methanol (19: 1)], octadecylsilanization (ODS) silica gel column chromatography [acetonitrile-water (1: 1)], Sephadex LH-20 [methanol], Fractions were fractionated (fractions C-1 to C-5). Fraction C-3 was dissolved in methanol and allowed to stand at room temperature, resulting in precipitation. The precipitate was collected by filtration, silica gel column chromatography [chloroform-methanol (30: 1; 19: 1)], ODS
Purification by repeated silica gel column chromatography [acetonitrile-water (1: 1)] and semi-preparative ODS HPLC [acetonitrile-methanol-water (1: 1: 1)] yields actin (3.2 g). Released.

ストレス緩和作用の検討
6適齢のBALB/c雄性マウスを用いて検討した。1週間予備飼育後、7週齢の時点でアクティン100mg/kgを経口投与した。投与30分後よりマウスを30mlの注射用シリンジ内に閉じ込めるストレスを1時間負荷し、直後に採血を行い血漿中のコルチコステロン濃度、LHD濃度を測定した。表1に示す通り試験群は対照群と比較して、有意に各パラメーターの上昇を抑制した。
表1:アクティンのストレス緩和効果

コルチコステロン(ng/m1) LDH(IU/1)

対照群 687.0±32.0 948.4±54.5
アクティン群 361.0±41.3** 345.5±44.5**

(n=5、平均値±標準偏差、**p<0.01)
表1に示す通り試験群は対照群に比較して、有意に各パラメータの上昇を用量依存的に抑制した。
Examination of stress relieving effect 6 Examination was performed using BALB / c male mice of appropriate ages. Actin 100 mg / kg was orally administered at the age of 7 weeks after preliminary breeding for 1 week. From 30 minutes after the administration, a stress for trapping the mouse in a 30 ml syringe was loaded for 1 hour, and blood was collected immediately after that to measure the corticosterone concentration and LHD concentration in plasma. As shown in Table 1, the test group significantly suppressed the increase in each parameter as compared with the control group.
Table 1: Stress relieving effect of Actin

Corticosterone (ng / m1) LDH (IU / 1)

Control group 687.0 ± 32.0 98.4 ± 54.5
Actin group 361. 0 ± 41.3 3 ** 345.5 ± 44.5 5 **

(N = 5, mean ± standard deviation, ** p <0.01)
As shown in Table 1, the test group significantly suppressed the increase of each parameter in a dose-dependent manner as compared with the control group.

(トローチ剤)
アラビアゴム 6.0
ステアリン酸マグネシウム 3.0
ブドウ糖 73.0
乳糖 17.6
リン酸第2カリウム 0.2
リン酸第1カリウム 0.1
香料 0.0995
アクティン 0.0005
合計 100.0
上記の各重量部の各成分を用い、常法に従ってトローチ剤とした。
(Troche)
Gum arabic 6.0
Magnesium stearate 3.0
Glucose 73.0
Lactose 17.6
Dibasic potassium phosphate 0.2
Potassium phosphate 0.1
Perfume 0.0995
Actin 0.0005
Total 100.0
Using each component of each of the above parts by weight, a lozenge was prepared according to a conventional method.

(飴)
ショ糖 20.0
水飴(75%固形分) 70.0
水 9.5
着色料 0.45
香料 0.0495
アクティン 0.0005
合計 100.0
上記の各重量部の各成分を用い、常法に従って飴とした。
(candy)
Sucrose 20.0
Chickenpox (75% solids) 70.0
Water 9.5
Coloring agent 0.45
Perfume 0.0495
Actin 0.0005
Total 100.0
Using each component of each of the above-mentioned parts by weight, it was made into a bowl according to a conventional method.

(チューインガム)
ガムベース 20.0
炭酸カルシウム 2.0
乳糖 77.0
ステビオサイド 0.0995
アクティン 0.0005
香料 0.9
合計 100.0
上記の各重量部の各成分を用い、常法に従ってチューインガムとした。
(Chewing gum)
Gum base 20.0
Calcium carbonate 2.0
Lactose 77.0
Stevioside 0.0995
Actin 0.0005
Fragrance 0.9
Total 100.0
A chewing gum was prepared in accordance with a conventional method using each component of each part by weight.

(ジュース)
濃縮ミカン果汁 15.0
果糖 5.0
クエン酸 0.2
香料 0.1
色素 0.15
アスコルビン酸ナトリウム 0.0498
アクティン 0.0002
水 79.5
合計 100.0
上記の各重量部の各成分を用い、常法に従ってジュースとした。
(juice)
Concentrated tangerine juice 15.0
Fructose 5.0
Citric acid 0.2
Fragrance 0.1
Dye 0.15
Sodium ascorbate 0.0498
Actin 0.0002
Water 79.5
Total 100.0
Using each component of the above-mentioned parts by weight, juice was prepared according to a conventional method.

(クッキー)
薄力粉 32.0
全卵 16.0
バター 16.0
砂糖 25.0
水 10.8
ベーキングパウダー 0.1998
アクティン 0.0002
合計 100.0
上記の各重量部の各成分を用い、常法に従ってクッキーとした。
(cookie)
Soft flour 32.0
Whole egg 16.0
Butter 16.0
Sugar 25.0
Water 10.8
Baking powder 0.1998
Actin 0.0002
Total 100.0
Using each component of the above-mentioned parts by weight, a cookie was prepared according to a conventional method.

(キャラメル)
グラニュー糖 31.0
水飴(75%固形分) 20.0
粉乳 40.0
硬化油 5.0
食塩 0.6
香料 0.0295
アクティン 0.0005
水 3.37
合計 100.0
上記の各重量部の各成分を用い、常法に従ってキャラメルとした。
(caramel)
Granulated sugar 31.0
Chickenpox (75% solids) 20.0
Milk powder 40.0
Hardened oil 5.0
Salt 0.6
Perfume 0.0295
Actin 0.0005
Water 3.37
Total 100.0
Caramel was prepared according to a conventional method using each of the above components by weight.

(錠剤、カプセル剤)
アクティン 1.0
乳糖 84.0
ステアリン酸マグネシウム 15.0
合計 100.0
上記の各重量部を均一に混合し、常法に従って錠剤、カプセル剤とした。
(Tablets and capsules)
Actin 1.0
Lactose 84.0
Magnesium stearate 15.0
Total 100.0
The above respective parts by weight were uniformly mixed, and tablets and capsules were prepared according to a conventional method.

(散剤、顆粒剤)
アクティン 2.0
澱粉 48.0
乳糖 50.0
合計 100.0
上記の各重量部を均一に混合し、常法に散剤、顆粒剤とした。
(Powder, granule)
Actin 2.0
Starch 48.0
Lactose 50.0
Total 100.0
The above respective parts by weight were uniformly mixed to obtain powders and granules in a conventional manner.

(注射剤)
アクティン 0.1
界面活性剤 9.0
生理食塩水 90.9
合計 100.0
上記の各重量部を加熱混合、滅菌して注射剤とした。
(Injection)
Actin 0.1
Surfactant 9.0
Saline 90.9
Total 100.0
Each of the above weight parts was mixed by heating and sterilized to obtain an injection.

Claims (3)

アクティンを有効成分とするストレス緩和剤。 A stress relieving agent containing actin as an active ingredient. アクティンを含有するストレス緩和作用を有する組成物。 Composition having a stress relaxation effect containing activate emissions. 組成物が食品、栄養補助食品、機能性食品または医薬品である請求項の組成物。 The composition according to claim 2 , wherein the composition is a food, a dietary supplement, a functional food or a pharmaceutical.
JP2003338518A 2003-09-29 2003-09-29 Stress relieving agent Expired - Fee Related JP4210190B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003338518A JP4210190B2 (en) 2003-09-29 2003-09-29 Stress relieving agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003338518A JP4210190B2 (en) 2003-09-29 2003-09-29 Stress relieving agent

Publications (2)

Publication Number Publication Date
JP2005104877A JP2005104877A (en) 2005-04-21
JP4210190B2 true JP4210190B2 (en) 2009-01-14

Family

ID=34534012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003338518A Expired - Fee Related JP4210190B2 (en) 2003-09-29 2003-09-29 Stress relieving agent

Country Status (1)

Country Link
JP (1) JP4210190B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170086120A (en) 2014-11-28 2017-07-25 모리나가 뉴교 가부시키가이샤 Agent for preventing or improving symptoms caused by imbalance of sex hormones

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013007807A1 (en) * 2011-07-12 2013-01-17 Bionorica Se Selected cimicifuga fractions for the treatment of osteoporosis
EP2545932A1 (en) * 2011-07-12 2013-01-16 Bionorica Se Selected cimicifuga fractions for treating osteoporosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170086120A (en) 2014-11-28 2017-07-25 모리나가 뉴교 가부시키가이샤 Agent for preventing or improving symptoms caused by imbalance of sex hormones

Also Published As

Publication number Publication date
JP2005104877A (en) 2005-04-21

Similar Documents

Publication Publication Date Title
Hyun et al. Physiological and pharmacological features of the non-saponin components in Korean Red Ginseng
Kaur et al. Pharmacological actions of Opuntia ficus indica: A Review
Abenavoli et al. Milk thistle in liver diseases: past, present, future
RU2294208C2 (en) Using treated ginseng extract and saponins isolated from its
EP3116520B1 (en) Phytocomplexes from citrus bergamia
KR101392204B1 (en) Composition comprising herbal extract of red ginseng, Angelicae gigantis Radix, citrus peel and green tea leaves for treating or preventing vascular diseases
KR101150643B1 (en) A composition comprising the compounds isolated from the Inulae Flos extract of Inula japonica Thunberg having anti-inflammatory or anti-allergic activity
JP5275251B2 (en) Composition comprising an extract of a combined herb for preventing and treating liver disease
US20100112101A1 (en) Bio-availability/bio-efficacy enhancing activity of stevia rebaudiana and extracts and fractions and compounds thereof
KR20150005430A (en) Composition for relieving premenstrual syndrome and menstrual pain
US7514104B2 (en) Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory
Jalili et al. An overview of therapeutic potentials of Taraxacum officinale (dandelion): A traditionally valuable herb with a reach historical background
KR101336094B1 (en) Functional food composition for improving skin condition and preparation method thereof
KR101043212B1 (en) A food for improving brain function
JP4210190B2 (en) Stress relieving agent
KR100522579B1 (en) Pharmaceutical composition comprising the extracts of scutellaria root and schizandra fruit mixture thereof having an effect of restraint stress
KR20140066480A (en) A composition comprising the extract of processed panax genus plant for preventing vascular smooth muscle cell proliferation and foam cell formation
JP4605984B2 (en) Stress relieving agent
KR101842786B1 (en) A composition for treating atopic dermatitis comprising the extract of herbal mixture
WO2022070013A1 (en) Bioactive compounds extraction from plant matters of silybum marianum and usage
Bhatnagar A comprehensive review of kalmegh’s biological activities (Andrographis paniculata)
JP2005213216A (en) Agent for relieving stress
JPH06340542A (en) Bone disease-preventing and treating agent originated from medicinal plant
KR101671571B1 (en) A ginseng seed composition having inhibitory effect of glucose absorption and preparing method thereof
JPH07101868A (en) Preventing and therapeutic agent for osteopathy containing extract of plant belonging to genus sambucus as active ingredient

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20030930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080708

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081021

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081024

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111031

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111031

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111031

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111031

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121031

Year of fee payment: 4

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121031

Year of fee payment: 4

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees